Septerna, Inc. (SEPN) Price & Analysis

Compare

86 Followers

SEPN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.17 - $28.99

Previous CloseN/A

Volume49.14K

Average Volume (3M)244.00K

Market Cap

$629.54M

Enterprise Value$164.84M

Total Cash (Recent Filing)$326.56M

Total Debt (Recent Filing)$24.57M

Price to Earnings (P/E)―

Beta2.76

Next Earnings

Nov 19, 2025

EPS Estimate

0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.56

Shares Outstanding44,585,136

10 Day Avg. Volume252,879

30 Day Avg. Volume244,005

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.26

Enterprise Value/Revenue227.05

Enterprise Value/Gross Profit227.05

Enterprise Value/Ebitda-1.64

Forecast

1Y Price Target

$23.00

Price Target Upside62.89% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe initiation of dosing for SEP-631 is considered a meaningful value inflection point for Septerna.

Financial PositionSepterna has approximately $421M in cash, providing sufficient financing into early 2028.

Strategic PartnershipsThe up to $2.2B collaboration with Novo provides important validation of SEPN's GPCR Native Complex platform in a very synergistic way with a global leader in obesity.

Bears Say

Clinical Program SetbackSEP-786 was discontinued due to unexpected, off-target toxicity in 2 MAD patients, but the adverse effect was reversible and did not lead to liver injury.

Uncertainty In DevelopmentSEP-631 (MRGPRX2 NAM) is now initiating a Ph1 healthy volunteer study, but the outcome remains uncertain as it assesses safety, tolerability, pharmacokinetics, and pharmacodynamics.

Septerna, Inc. News

Septerna doses first participants in Phase 1 trial of SEP-631

Septerna (SEPN) announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a...

16d ago

SEPN

Septerna Updates Presentation on Drug Discovery Progress

An update from Septerna, Inc. ( ($SEPN) ) is now available. On September 3, 2025, Septerna, Inc. updated...

3d ago

SEPN

Septerna, Inc.: Advancements in Clinical Trials and Strategic Focus Drive Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Septerna, Inc.. The associated price target...

16d ago

SEPN

Septerna Begins Phase 1 Trial for SEP-631

The latest announcement is out from Septerna, Inc. ( ($SEPN) ). On August 21, 2025, Septerna, Inc. announced...

16d ago

SEPN

Septerna Reports Q2 2025 Financial Results and Progress

Septerna, Inc. ( ($SEPN) ) has released its Q2 earnings. Here is a breakdown of the information Septerna,...

25d ago

SEPN

Septerna Appoints Liz Bhatt as New President

Septerna, Inc. ( ($SEPN) ) has provided an announcement. On July 30, 2025, Septerna, Inc. announced the appointment...

1M ago

SEPN

Septerna Announces Collaboration with Novo Nordisk

Septerna, Inc. ( ($SEPN) ) just unveiled an announcement. On July 1, 2025, Septerna, Inc. announced the effectiveness...

2M ago

SEPN

Septerna initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Septerna (SEPN) with a Buy rating and $26 price target Septerna is an...

3M ago

SEPN

Septerna, Inc. Holds Virtual Annual Stockholders Meeting

An update from Septerna, Inc. ( ($SEPN) ) is now available. On June 17, 2025, Septerna, Inc. conducted...

3M ago

SEPN

Sector Spotlight: Trump executive order targets drug prices

Welcome to the latest edition of “Sector Spotlight,” where The Fly looks at a new industry every week...

4M ago

BMY

Septerna price target raised to $18 from $11 at Wells Fargo

Wells Fargo analyst Derek Archila raised the firm’s price target on Septerna (SEPN) to $18 from $11 and...

4M ago

NVO

SEPN

Septerna, Inc.: Strategic Partnerships and Promising Pipeline Drive Buy Rating

TD Cowen analyst Yaron Werber has maintained their bullish stance on SEPN stock, giving a Buy rating yesterday....

4M ago

SEPN

Septerna reports Q1 EPS (49c), consensus (45c)

Reports Q1 revenue $219,000 vs. $317,000 last year. “Yesterday’s landmark partnership announcement with Novo Nordisk to advance our...

4M ago

SEPN

Novo Nordisk (NVO) Signs $2.2B Deal to Develop Weight-Loss Pills

Pharma company Novo Nordisk ($NVO) has signed a $2.2 billion partnership with biotech firm Septerna ($SEPN) in order...

4M ago

NVO

SEPN

SEPN FAQ

What was Septerna, Inc.’s price range in the past 12 months?

Septerna, Inc. lowest stock price was $4.17 and its highest was $28.99 in the past 12 months.

What is Septerna, Inc.’s market cap?

Septerna, Inc.’s market cap is $629.54M.

When is Septerna, Inc.’s upcoming earnings report date?

Septerna, Inc.’s upcoming earnings report date is Nov 19, 2025 which is in 74 days.

How were Septerna, Inc.’s earnings last quarter?

Septerna, Inc. released its earnings results on Aug 11, 2025. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of $0.927 by -$1.487.

Is Septerna, Inc. overvalued?

According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Septerna, Inc. pay dividends?

Septerna, Inc. does not currently pay dividends.

What is Septerna, Inc.’s EPS estimate?

Septerna, Inc.’s EPS estimate is 0.04.

How many shares outstanding does Septerna, Inc. have?

Septerna, Inc. has 44,585,136 shares outstanding.

What happened to Septerna, Inc.’s price movement after its last earnings report?

Septerna, Inc. reported an EPS of -$0.56 in its last earnings report, missing expectations of $0.927. Following the earnings report the stock price went down -2.524%.

Which hedge fund is a major shareholder of Septerna, Inc.?

Currently, no hedge funds are holding shares in SEPN

Septerna, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-32.78%

Trailing 12-Months

Asset Growth

135.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Septerna, Inc.

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Septerna, Inc. (SEPN) Earnings & Revenues

Historic Earnings Reports

SEPN Stock 12 Month Forecast

Average Price Target

$23.00

▲(62.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","16":"$16","27":"$27","10.5":"$10.5","21.5":"$21.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10.5,16,21.5,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.34,13.39076923076923,14.44153846153846,15.492307692307692,16.543076923076924,17.59384615384615,18.644615384615385,19.695384615384615,20.746153846153845,21.796923076923076,22.847692307692306,23.89846153846154,24.949230769230766,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.34,13.16,13.98,14.8,15.620000000000001,16.44,17.259999999999998,18.08,18.9,19.72,20.54,21.36,22.18,{"y":23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.34,12.775384615384615,13.21076923076923,13.646153846153846,14.081538461538461,14.516923076923076,14.952307692307691,15.387692307692308,15.823076923076922,16.25846153846154,16.693846153846152,17.12923076923077,17.564615384615387,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.75,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.75,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.75,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.75,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.79,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.79,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.47,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.21,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >